Estradiol valerate and estradiol valerate/dienogest (natazia) tablets: the first four-phasic oral contraceptive.

In: P & T : a peer-reviewed journal for formulary management · 2010 · vol. 35(11) , pp. 614–7 · PMID:21139816 · W1414717823
article OA: green CC0
🔓 Open OA copy View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-09

This article reviews the indications, pharmacology, clinical trials, adverse effects, drug interactions, contraindications, warnings, dosage, and cost of the first four-phasic oral contraceptive, estradiol valerate and estradiol valerate/dienogest (Natazia) tablets.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This article focuses upon the May 2010 FDA approved estradiol valerate and estradiol valerate/dienogest (Natazia) tablets which is the first four-phasic oral contraceptive. It discusses: the indications and usage the clinical pharmacology including mechanism of action and pharmacokinetics clinical trials adverse drug effects drug interactions contraindications warnings dosage and administration and cost.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (6)

Source provenance

openalex
last seen: 2026-05-10T11:57:47.865992+00:00
License: CC0 · commercial use OK